The Utah Mammoth announced today that the public side of the practice and training facility in Sandy, Utah will begin offering a range of programming for people of all ages and experience levels on ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Learn how to use advanced techniques like short-circuiting, parallel execution, virtual threads, and stream gatherers to maximize Java stream performance. My recent Java Stream API tutorial introduced ...

What does it take to become the best at something? The answer may not lie in early childhood excellence or in lifelong, laser-focused dedication. Instead the path to becoming exceptional at a skill ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Financial Services Company Awards $42,000+ in Support to Help Three Therapists Launch Private Practices SEATTLE--(BUSINESS WIRE)--Heard, a leading financial services platform for health and wellness ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.